PV Bulletin

Swissmedic Guidance on Injectable Products for Wrinkle Treatment

Updated guidance clarifying the classification and professional use requirements for injectable aesthetic products, such as botulinum toxin and dermal fillers.

Primary source: Swissmedic

PV Impact Brief

Urgency: HighConfidence: high

What changed

Botulinum toxin is now confirmed as prescription-only, and strict safety and professional use requirements for dermal fillers are mandated under the MedDO.

Why it matters

These changes necessitate healthcare professionals to adhere to new reporting and compliance measures concerning injectable products, ultimately aiming to enhance patient safety.

Action needed

Healthcare professionals must report all serious incidents involving injectable devices to Swissmedic as outlined in the new guidance.

Relevant for
Regulatory Intelligence LeadQPPV
Processes impacted
Country Compliance
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Guidance
Policy status
final
Publication date
June 19, 2026
Policy change
Updated guidance clarifying the regulatory classification and professional use requirements for injectable aesthetic products, such as botulinum toxin and dermal fillers.

Key changes

Confirms botulinum toxin as prescription-only; mandates strict safety and professional use requirements for dermal fillers under MedDO.

Affected workflows

Country Compliance

Responsible groups

MAHsMedical Affairs

PV impact

Reinforces risk management and safety monitoring for aesthetic medicinal products and devices.

View regulator source

Source document details

Exact policy details

Version
4.0
Applies to: Applicable to the information sheet on injectable products for wrinkle treatment.
Document version stated on page 1. · p. 1 · High · Source
Valid from
19.06.2026
Applies to: Date from which the version of the document is effective.
Effective date noted on page 1. · p. 1 · High · Source
Authorization Requirement for Injectable Products
Botulinum toxin must be authorized as medicinal products.
Applies to: Applies to all injectable products classified as medicinal products.
Stated on page 3 regarding botulinum toxin preparations. · p. 3 · High · Source
Conformity Assessment Requirement
Products containing hyaluronic acid, along with others, must undergo a conformity assessment procedure.
Applies to: Applicable to injectable products regulated by the Medical Devices Ordinance.
Highlighted on page 4 and page 6. · p. 4 · High · Source
Reporting Obligation
Healthcare professionals must report all serious incidents involving the use of such devices to Swissmedic.
Applies to: Mandatory for users of injectable devices.
Noted on page 5 under Art. 66 para. 4 MedDO. · p. 5 · High · Source

Extracted documents

Evidence and confidence

Confidence: highSource updated: Jun 19, 2026

Full briefing

Practical implication

Healthcare professionals must report all serious incidents involving injectable devices to Swissmedic as outlined in the new guidance.

The updated information sheet from Swissmedic specifies that botulinum toxin is classified as a prescription-only medicinal product, while dermal fillers are subject to safety and professional use requirements as per the Medical Devices Ordinance (MedDO). It emphasizes mandatory risk management and safety monitoring for these aesthetic products.

What changed: Botulinum toxin is now confirmed as prescription-only, and strict safety and professional use requirements for dermal fillers are mandated under the MedDO.

Why it matters: These changes necessitate healthcare professionals to adhere to new reporting and compliance measures concerning injectable products, ultimately aiming to enhance patient safety.

Practical implication: Healthcare professionals must report all serious incidents involving injectable devices to Swissmedic as outlined in the new guidance.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Safety Signals#final#policy-change#Guidance#firecrawl-policy-agent#Swissmedic

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Atellica CH Revised C-Reactive Protein (RCRP) Safety Information - Siemens Healthcare Diagnostics

Urgency: High

Laboratories must implement the safety measures as indicated by the action registration number R2625739, effective from the notice date of September 7, 2026.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward